325 related articles for article (PubMed ID: 28108737)
1. Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Cai Y; Dodhia S; Su GH
Oncotarget; 2017 Mar; 8(13):22203-22217. PubMed ID: 28108737
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
Isaacsson Velho PH; Castro G; Chung CH
Am Soc Clin Oncol Educ Book; 2015; ():123-8. PubMed ID: 25993150
[TBL] [Abstract][Full Text] [Related]
3. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
5. Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck.
Simpson DR; Mell LK; Cohen EE
Oral Oncol; 2015 Apr; 51(4):291-8. PubMed ID: 25532816
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
7. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Wirtz ED; Hoshino D; Maldonado AT; Tyson DR; Weaver AM
JAMA Otolaryngol Head Neck Surg; 2015 Jun; 141(6):543-9. PubMed ID: 25855885
[TBL] [Abstract][Full Text] [Related]
8. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
Anderson RT; Keysar SB; Bowles DW; Glogowska MJ; Astling DP; Morton JJ; Le P; Umpierrez A; Eagles-Soukup J; Gan GN; Vogler BW; Sehrt D; Takimoto SM; Aisner DL; Wilhelm F; Frederick BA; Varella-Garcia M; Tan AC; Jimeno A
Mol Cancer Ther; 2013 Oct; 12(10):1994-2005. PubMed ID: 23873848
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Theurer JA; Stecho W; Yoo J; Kwan K; Wehrli B; Harry V; Black M; Pinto N; Winquist E; Palma D; Richter S; Barrett JW; Danielle MacNeil S; Fung K; Howlett CJ; Nichols AC
Pathol Oncol Res; 2016 Jan; 22(1):35-40. PubMed ID: 26271341
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathways in head and neck cancer: EGFR, PI3K, and more.
Psyrri A; Seiwert TY; Jimeno A
Am Soc Clin Oncol Educ Book; 2013; ():246-55. PubMed ID: 23714515
[TBL] [Abstract][Full Text] [Related]
11. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
Akbari Dilmaghani N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Bashash D
IUBMB Life; 2021 Apr; 73(4):618-642. PubMed ID: 33476088
[TBL] [Abstract][Full Text] [Related]
12. Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets.
Iglesias-Bartolome R; Martin D; Gutkind JS
Cancer Discov; 2013 Jul; 3(7):722-5. PubMed ID: 23847349
[TBL] [Abstract][Full Text] [Related]
13. Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.
Lee MJ; Jin N; Grandis JR; Johnson DE
Biochim Biophys Acta Mol Cell Res; 2020 Jun; 1867(6):118679. PubMed ID: 32061630
[TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
Mazumdar T; Byers LA; Ng PK; Mills GB; Peng S; Diao L; Fan YH; Stemke-Hale K; Heymach JV; Myers JN; Glisson BS; Johnson FM
Mol Cancer Ther; 2014 Nov; 13(11):2738-50. PubMed ID: 25193510
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling.
Du L; Chen X; Cao Y; Lu L; Zhang F; Bornstein S; Li Y; Owens P; Malkoski S; Said S; Jin F; Kulesz-Martin M; Gross N; Wang XJ; Lu SL
Oncogene; 2016 Sep; 35(35):4641-52. PubMed ID: 26876212
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer.
Tonlaar N; Galoforo S; Thibodeau BJ; Ahmed S; Wilson TG; Yumpo Cardenas P; Marples B; Wilson GD
Radiother Oncol; 2017 Sep; 124(3):504-512. PubMed ID: 28823407
[TBL] [Abstract][Full Text] [Related]
18. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
Azoury SC; Gilmore RC; Shukla V
Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
[TBL] [Abstract][Full Text] [Related]
19. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
20. The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck.
Rogers SJ; Box C; Harrington KJ; Nutting C; Rhys-Evans P; Eccles SA
Expert Opin Ther Targets; 2005 Aug; 9(4):769-90. PubMed ID: 16083342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
